Methodology of antiemetic trials: Response assessment, evaluation of new agents and definition of chemotherapy emetogenicity

Supportive Care in Cancer

Volumn 6, Issue 3, 1998, Pages 221-227

  Hesketh, Paul J ^a   Gralla, Richard J ^b   Du Bois, Andreas ^c   Tonato, Maurizio ^d  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b Ochsner Cancer Institute   (United States)

^c St Vincentius Hospital   (Germany)

^d POLICLINICO MONTELUCE   (Italy)

Author keywords

Antiemetic; Emesis; Emetogenicity; Methodology; Nausea

Indexed keywords

ANTIEMETIC AGENT;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 0031922859     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050157     Document Type: Review

References (32)

1. Aapro M (1993) Methodological issues in antiemetic studies. Investigational New Drugs 11:243-253
2. Beck TM, Ciociola AA, Jones SE, et al (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-113
3. Clark RA, Tyson LB, Frisone M (1985) A correlation of objective and subjective parameters in assessing anti-emetic regimens. Proc Tenth Ann Cong Oncol Nurs Soc 2:96
4. Craig JB, Powell BL (1987) The management of nausea and vomiting in clinical oncology (review). Am J Med Sci 34-44
5. Cubeddu LX, Hoffman IS, Fuenmayor NT, et al (1990) Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 8:1721-1727
6. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy. Am J Clin Oncol 17:137-146
7. D'Acquisto R, Tyson LB, Gralla RJ, et al (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5:257
8. DelFavero A, Roila F, Basurto C, et al (1990) Assessment of nausea. Eur J Clin Pharmacol 38:115
9. DelFavero A, Tonato M, Roila F (1992) Issues in the measurement of nausea. Br J Cancer 66 [Suppl]. S69-S71
10. DiBenedetto J Jr, Cubeddu LX, Ryan T, et al (1995) Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther 17:1091-1098
11. Fetting JH, Grochow LB, Folstein MF, et al (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487-1493
12. Geddes DM, Dones L, Hill E, et al (1990) Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer 26:484-492
13. Gralla RJ, Itri LM, Pisko SE, et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905-909
14. Gralla RJ, Clark RA, Kris MG, et al (1991) Methodology in anti-emetic trials. Eur J Cancer 27:S5-S8
15. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796
16. Havsteen H, Nielsen H, Kiaer M (1986) The use of visual analogue scale (VAS) in patiems receiving cisplatin-containing chemotherapy. Proc Am Soc Clin Oncol 5:263
17. Hesketh PJ, Murphy WK, Lester EP, et al (1989) GR 38032F (GR-C507/ 75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700-705
18. Hesketh PJ, Plagge P, Bryson JC (1992) Single-dose ondansetron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller AD, King GL (eds) Mechanisms and control of emesis. John Libbey, London, pp 25-26
19. Hesketh PJ, Kris MG, Grunberg SM, et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109
20. Holmes S, Eburn E (1989) Patients' and nurses' perceptions of symptom distress in cancer. J Adv Nurs 14:840-846
21. Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for theprevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5
22. Kris MG, Gralla RJ, Clark RA, et al (1985) Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69:1257-1262
23. Laszlo J (1982) Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 9:3-9
24. Lindley CM, Bernard S, Fields SM (1989) Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7:1142-1149
25. Martin M, Diaz Rubio E, Sanchez A, et al (1990) The natural course of emesis after carboplatin treatment. Acta Oncologica 29:593-596
26. Melzack R (1989) Measurement of nausea. J Pain Symptom Manage 4:157-160
27. Morrow GR (1984) The assessment of nausea and vomiting: past problems, current issues, and suggestions for future research. Cancer 53 [Suppl]: 2267-2278
28. Olver IN, Simon RM, Aisner J (1986) Antiemetic studies: a methodological discussion Cancer Treat Rep 70:555-563
29. Smyth JF (1988) The problem of emesis induced by cancer chemotherapy. Clinician 6:2-12
30. Strum SB, McDermed JE, Pileggi J, et al (1984) Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. Cancer 53:1432-1439
31. Tonato M, Roila F, DelFavero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107-114
32. Tonato M, Roila F, DelFavero A (1996) Methodology of trials with antiemetics. Support Care Cancer 4:281-286